SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-19-002219
Filing Date
2019-02-12
Accepted
2019-02-12 15:36:17
Documents
1
Group Members
ANDREW MARTINKEVIN RUSSELL

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G sc13g1218a1ubsoconn_orexigen.htm SC 13G/A 61825
  Complete submission text file 0001213900-19-002219.txt   63389
Mailing Address ONE NORTH WACKER DRIVE 32ND FLOOR CHICAGO IL 60606
Business Address ONE NORTH WACKER DRIVE 32ND FLOOR CHICAGO IL 60606 3125256000
UBS OCONNOR LLC (Filed by) CIK: 0001132716 (see all company filings)

IRS No.: 061569842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Subject) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-83422 | Film No.: 19590457
SIC: 2834 Pharmaceutical Preparations